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Rare diseases illuminate the most important molecular
steps along cell pathways. A clinical encounter with a
woman crippled by the autosomal dominant turban
tumour syndrome or cylindromatosis led us to chromo-
some 16 and the CYLD gene, later shown to be a key
regulator of ubiqitination in the NFkappa B pathway
and a potential target for high dose salicylate therapy. A
genome wide approach added dysregulated tropomyosin
kinase signaling (Trk).We developed an in vitro cylin-
droma primary cell culture model which permitted
experimental validation of Trk inhibitors as a viable
therapeutic approach.
Familial studies in our centre have focused on heredi-
tary cancer. Two large pedigrees led to collaboration
with Kolodner in identification of the mismatch repair
pathway and rapid entry into diagnostics which, in turn,
led to development in 1994 of our international CAPP2
randomised controlled trial of aspirin and resistant
starch in 1009 carriers of an MMR gene defect. We
have demonstrated, in prolonged double blind follow up
that taking 2 aspirins daily for 2 years results in a subse-
quent 60% reduction in new cancers at a mean of 5
y e a r s( p a p e ri np r e s s ) .C O X 2i n h i b i t i o ni sa nu n l i k e l y
sole mechanism for such delayed effects. Enhanced
apoptosis, similar to that seen in infected plants trig-
gered by natural salicylates, would explain the effect.
Another under-explored mechanism open to modulation
is the immune response to mismatch repair deficient
cells. Lymphocytic infiltration is the hallmark of these
tumours and recent studies by our research partners
have revealed striking levels of immune response to the
frame-shift derived neopeptides released by MMR defi-
cient cells. These antibody responses provide a credible
biomarker for our planned CAPP3 dose inferiority study
which will examine different doses of aspirin in 3000
gene carriers. This immunological discovery also opens
the way to possibility of a vaccine against the neopep-
tides which would have relevance for the 1 in 6 sporadic
cancers which manifest acquired MMR defects.
Simpler methods to investigate tumour genomes in
the pathology lab are needed because while aspirin can
be offered to all, most new therapies call for greater tar-
geting. . Our commercial venture, QuantuMDx hopes to
fill this gap. Tethering single strand DNA to a silicon
nanowire and sequencing with heavily charged chain
terminating nucleotides in a microfluidic vehicle offers
robust cheap genotyping “while you wait”,c o n v e r t i n g
chemistry to computerc o d ew i t h o u tt h e“middlemen”.
Affordable and reliable testing for microsatellite instabil-
ity and activating ras mutations could then be easily
incorporated into standard histopathology practice.
Proof of principle is anticipated within months and a
commercial device is planned within three years.
If the method proves to be as robust as we anticipate,
it offers cheap genotyping in pharmacies for common
variants such as the UGT1A6 polymorphisms which
modulate response to aspirin and would allow more
personalised dosing as we move towards a recommenda-
tion of general aspirin use in the over 50’sf o rp r e v e n -
tion of vascular events and cancer.
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